Clinical Significance of Hyperexpression of Epidermal Growth Factor Receptors (EGFR and HER-2) in Esophageal Squamous Cell Carcinoma

  • V. V. Delektorskaya
  • G. Yu. Chemeris
  • P. V. Kononets
  • A. Yu. Grigorchuk
Oncology
First Online:
Received:

Immunohistochemical study of marker expression in primary tumors of patients with esophageal squamous-cell carcinoma was carried out in order to evaluate prognostic significance of EGFR and HER-2 levels in the tumors. Hyperexpression of EGFR and HER-2 in the tumors is an important marker for the analysis of prognosis and clinical course of the disease. A relationship between high levels of EGFR and HER-2 in the tumors of patients with esophageal squamous-cell carcinoma and intravascular tumor invasion (p=0.038) and poor outcome of the disease (p=0.019) was detected. The results indicate that evaluation of changes in the expression of EGFR and HER-2 in tumors is essential for individual prediction of the disease course and development of new approaches to the treatment of these tumors, including target therapy aimed at these tyrosine kinase receptors.

Key Words

esophageal cancer immunohistochemistry EGFR HER-2 prognosis 
This is a preview of subscription content, log in to check access.

References

  1. 1.
    M. Akamatsu, T. Matsumoto, K. Oka, et al., Int. J. Radiat. Oncol. Biol. Phys., 57, No. 5, 1323–1327 (2003).PubMedGoogle Scholar
  2. 2.
    M. Dreilich, A. Wanders, D. Brattstrom, et al., Dis. Esophagus, 19, No. 4, 224–231 (2006).CrossRefPubMedGoogle Scholar
  3. 3.
    L. Gibault, J. P. Metges, V. Conan-Charlet, et al., Br. J. Cancer, 93, No. 1, 107–115 (2005).CrossRefPubMedGoogle Scholar
  4. 4.
    I. Gockel, M. Moehler, K. Frerichs, et al., Oncol. Rep., 20, No. 4, 845–850 (2008).PubMedGoogle Scholar
  5. 5.
    M. Gotoh, H. Takiuchi, S. Kawabe, et al., Jpn. J. Clin. Oncol., 37, No. 9, 652–657 (2007).CrossRefPubMedGoogle Scholar
  6. 6.
    M. Hanawa, S. Suzuki, Y. Dobashi, et al., Int. J. Cancer, 118, No. 5, 1173–1180 (2006).CrossRefPubMedGoogle Scholar
  7. 7.
    D. M. Lehrbach, M. E. Nita, and I. Cecconello, Arq. Gastroenterol., 40, No. 4, 256–261 (2003).CrossRefPubMedGoogle Scholar
  8. 8.
    D. C. Lin, X. L. Du, and M. R. Wang, Dis. Esophagus, 22, No. 1, 9–20 (2009).CrossRefPubMedGoogle Scholar
  9. 9.
    K. Mimura, K. Kono, M. Hanawa, et al., Br. J. Cancer, 92, No. 7, 1253–1260 (2005).CrossRefPubMedGoogle Scholar
  10. 10.
    S. Morgan and J. R. Grandis, Exp. Cell Res., 315, No. 4, 572–582 (2009).CrossRefPubMedGoogle Scholar
  11. 11.
    U. Reichelt, P. Duesedau, M. Tsourlakis, et al., Modern Pathol., 20, No. 1, 120–129 (2007).CrossRefGoogle Scholar
  12. 12.
    I. Rubin and Y. Yarden, Ann. Oncol., 12, Suppl. 1, S3–S8 (2001).CrossRefPubMedGoogle Scholar
  13. 13.
    Y. Sato-Kuwabara, J. I. Neves, J. H. Fregnani, et al., BMC Cancer, 9, 6 (2009).CrossRefPubMedGoogle Scholar
  14. 14.
    P. Sunpaweravong, S. Sunpaweravong, P. Puttawibul, et al., J. Cancer Res. Clin. Oncol., 131, No. 2, 111–119 (2005).CrossRefPubMedGoogle Scholar
  15. 15.
    Y. Yarden and M. X. Sliwkowski, Nat. Rev. Mol. Cell Biol., 2, No. 2, 127–137 (2001).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2009

Authors and Affiliations

  • V. V. Delektorskaya
    • 1
  • G. Yu. Chemeris
    • 1
  • P. V. Kononets
    • 1
  • A. Yu. Grigorchuk
    • 1
  1. 1.N. N. Blokhin Russian Cancer Research CenterRussian Academy of Medical SciencesMoscowRussia

Personalised recommendations